Hikma Pharmaceuticals Regulatory News (HIK)

21 Jan 2008 14:58

Hikma Pharmaceuticals Plc21 January 2008 Notification of transaction by Directors LONDON, 21 January 2008 - Hikma Pharmaceuticals PLC (the "Company") (LSE: HIK)(DIFX:HIK) announces that the Directors of the Company listed below, and DarholdLimited, being a connected person for the purposes of the Listing Rules,notified the Company on 17 January 2008, that they had undertaken the followingsubscriptions of shares as part of the of the placing undertaken by the Companyon that date: Name Shares Percentage of enlarged issued share Price subscribed capitalDarhold 5,233,056 2.783 480 penceLimitedSamih Darwazah 168,944 0.09 480 penceSaid Darwazah 60,665 0.032 480 penceMazen Darwazah 55,633 0.03 480 pence Following the notification, each of the Directors and Darhold Limited have thefollowing holdings of ordinary shares of 10 pence each in the capital of theCompany representing the percentages of the enlarged issued ordinary sharecapital of the Company set out below. Name No. Of Ordinary Percentage of enlarged issued Shares share capitalDarhold 57,883,028 30.783LimitedSamih Darwazah 1,875,450 0.997Said Darwazah 673,445 0.358Mazen Darwazah 617,591 0.328 Each of the above individuals is both a director and a Person DischargingManagerial Responsibility in respect of the Company. Darhold Limited isconnected with the above directors for the purposes of the Listing Rules. Theabove notification relates to DTR 3.1.4R(1)(a) and other Listing Rules. -- ENDS -- Enquiries: Hikma Pharmaceuticals PLCHenry Knowles +44 20 7399 2760Company SecretarySusan Ringdal +44 20 7399 2760Investor Relations Director Brunswick GroupJon Coles / Justine McIlroy / Alex Tweed +44 20 7404 5959 About Hikma Hikma Pharmaceuticals PLC is a fast growing multinational group focused ondeveloping, manufacturing and marketing a broad range of both branded andnon-branded generic and in-licensed pharmaceutical products. Hikma's operationsare conducted through three businesses: "Branded", "Injectables" and "Generics".Hikma's operations are based principally in the Middle East and North Africa("MENA") region, where it is a market leader and sells across 17 countries, theUnited States and Europe. In 2006, the Group achieved revenues of $317 million(2005 $262 million) and profit attributable to shareholders was $55 million(2005 $44 million). At 30 June 2007, the Group had over 2,700 employees. Fornews and other information, please visit www.hikma.com. This information is provided by RNS The company news service from the London Stock Exchange